Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspartylchlorin p6 dimethylester (7b) is a chlorin p6-based photosensitizer developed for photodynamic therapy (PDT). It is a water-soluble amino acid conjugate designed to overcome limitations of traditional photosensitizers, such as poor solubility and high dark toxicity. In preclinical studies, 7b demonstrated significant phototoxicity against melanoma cells while maintaining low dark toxicity, outperforming verteporfin in both in vitro and in vivo B16-F10 tumor models. The compound localizes in multiple subcellular organelles and induces cell death through both necrosis and apoptosis upon light activation within the phototherapeutic window. Its mechanism involves the generation of singlet oxygen, leading to effective tumor destruction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspartylchlorin p6 dimethylester.